Friday, September 23, 2016

Faruqi & Faruqi, LLP Investigation: Raptor Pharmaceutical Corp. (RPTP)

Faruqi & Faruqi, LLP Announces the Investigation of Raptor Pharmaceutical Corp. (RPTP) Over the Proposed Sale of the Company to Horizon Pharma plc


Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Raptor Pharmaceutical Corp. (“Raptor Pharmaceuticals” or the “Company”) (NASDAQ: RPTP) for potential breaches of fiduciary duties in connection with the sale of the Company to Horizon Pharma plc for approximately $800 million.

The Company’s stockholders will only receive $9.00 in cash for each share of Company common stock they own. However, this consideration is below at least one analyst’s price target of $10.00 per share.

The investigation focuses on whether Raptor Pharmaceutical’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Raptor Pharmaceutical’s shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation.  The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.

Faruqi & Faruqi, LLP is working together in this investigation with Juan E. Monteverde from Monteverde & Associates PC.

If you own common stock in Raptor Pharmaceutical and wish to obtain additional information and protect your investments free of charge, please visit us at or contact Nadeem Faruqi, Esq. either via e-mail at or by telephone at (877) 247-4292 or (212) 983-9330.  You may also contact Juan E. Monteverde, Esq.  either via email at or by telephone at (212) 971-1341.

No comments:

Post a Comment